Alumis News & Analysis
2 articles
Market Mood
Alumis Stock Price Target Adjusted to $25 Amid Competitive Pressures
H.C. Wainwright has lowered its price target for Alumis's stock to $25, citing competitive pressures in the market. This adjustment reflects concerns regarding market dynamics that could impact the company's performance. As a result, this change may influence investor sentiment and trading strategies for Alumis shares going forward.
Read More
Alumis' Phase 3 Trial Results for Envudeucitinib Show Significant Efficacy
Alumis announced results from a Phase 3 trial of envudeucitinib for psoriasis indicating a significant percentage of participants achieved the primary endpoint. Specific efficacy rates were reported at 70% for the treatment group compared to 30% for the placebo group. The trial included over 300 participants, which supports further developments and potential regulatory submission. These results could impact Alumis' stock performance positively as they advance towards commercialization.
Read More